Louisiana State Employees Retirement System Takes Position in Amneal Pharmaceuticals, Inc. $AMRX

Louisiana State Employees Retirement System bought a new stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) during the first quarter, HoldingsChannel.com reports. The fund bought 75,300 shares of the company’s stock, valued at approximately $936,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in AMRX. Spire Wealth Management boosted its holdings in Amneal Pharmaceuticals by 66.6% during the fourth quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock valued at $32,000 after purchasing an additional 1,023 shares in the last quarter. Intech Investment Management LLC grew its stake in shares of Amneal Pharmaceuticals by 1.2% in the 4th quarter. Intech Investment Management LLC now owns 97,573 shares of the company’s stock valued at $1,229,000 after purchasing an additional 1,159 shares during the period. Hsbc Holdings PLC raised its holdings in shares of Amneal Pharmaceuticals by 1.6% in the 4th quarter. Hsbc Holdings PLC now owns 101,945 shares of the company’s stock worth $1,297,000 after buying an additional 1,569 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Amneal Pharmaceuticals by 2.4% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 68,137 shares of the company’s stock worth $859,000 after buying an additional 1,582 shares during the period. Finally, Comerica Bank lifted its position in shares of Amneal Pharmaceuticals by 56.1% during the 4th quarter. Comerica Bank now owns 4,690 shares of the company’s stock worth $59,000 after buying an additional 1,685 shares during the period. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Stock Performance

Shares of AMRX stock opened at $17.15 on Monday. Amneal Pharmaceuticals, Inc. has a 1 year low of $7.66 and a 1 year high of $17.86. The firm’s 50 day moving average is $14.21 and its 200-day moving average is $13.58. The firm has a market capitalization of $5.47 billion, a price-to-earnings ratio of 45.13 and a beta of 1.26.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.27 earnings per share for the quarter. Amneal Pharmaceuticals had a net margin of 4.01% and a negative return on equity of 313.96%. The business had revenue of $722.52 million during the quarter. On average, equities research analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.92 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have weighed in on AMRX. Zacks Research cut Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. Wall Street Zen cut Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, June 29th. Barclays boosted their target price on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Wednesday, May 20th. Weiss Ratings cut shares of Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, May 26th. Finally, UBS Group initiated coverage on shares of Amneal Pharmaceuticals in a report on Friday, April 17th. They set a “buy” rating and a $19.00 price target for the company. Five analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, Amneal Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $15.80.

Insider Buying and Selling

In other news, Director Deborah M. Autor sold 34,819 shares of Amneal Pharmaceuticals stock in a transaction on Monday, May 11th. The stock was sold at an average price of $12.94, for a total value of $450,557.86. Following the completion of the sale, the director directly owned 93,660 shares of the company’s stock, valued at approximately $1,211,960.40. This trade represents a 27.10% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 17.30% of the company’s stock.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.